Rheumatic arthritis is an autoimmune disease where the immune system mistakenly attacks the lining of joints, causing inflammation and permanent joint destruction over time. It is caused by a combination of genetic and environmental factors. Symptoms include symmetrical joint pain, swelling, stiffness, and loss of function. Treatment aims to relieve pain, prevent further joint damage, and maintain normal life activities. Treatment options include non-pharmacological therapies like exercise and diet changes as well as disease-modifying drugs and corticosteroids to slow disease progression and manage symptoms.
A proper description about Rheumatic arthritis. It containts DEFINITION, EPIDEMIOLOGY, ETIOLOGY, RISK FACTORS, PATHOPHYSILOGY, SIGN & SYMPTOMS, DIAGNOSIS, TREATMENT & DIFFERENCES BETWEEN RA & OA
A proper description about Rheumatic arthritis. It containts DEFINITION, EPIDEMIOLOGY, ETIOLOGY, RISK FACTORS, PATHOPHYSILOGY, SIGN & SYMPTOMS, DIAGNOSIS, TREATMENT & DIFFERENCES BETWEEN RA & OA
Living with rheumatoid arthritis is challenging. Besides the benefit of getting shortly on medication after diagnosis, lifestyle modifications play an important role in rheumatoid arthritis management. Diet, exercise, sleep, medication can be very helpful.
Living with rheumatoid arthritis is challenging. Besides the benefit of getting shortly on medication after diagnosis, lifestyle modifications play an important role in rheumatoid arthritis management. Diet, exercise, sleep, medication can be very helpful.
The current presentation include the pharmacotherapy for rheumatoid arthritis. The definition, classification, mechanism of action of drugs, pharmacokinetics, adverse effects, contraindications and uses.
Overview of Discussion-
Anti-rheumatoid drugs
Classification of anti-rheumatoid drugs
Pharmacology of disease modifying anti-rheumatic drugs (DMARDs)
Pharmacology of adjuvant drugs
DMARDs and biologics have made a huge difference in the lives of people with RA and other rheumatologic disorders. Biologics era was showed+ in the year 1998 with the FDA approval of TNF antagonist and etanercept. Biologics bring the disease under control in 4–6 weeks compared to 3–6 months taken by traditional DMARDs.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. What is rheumatic arthritis?
When immune system of body mistakenly attacks on lining tissue (synovium) of
joint, joint become inflammed results over prodution of joint fluid (synovial
fluid)and cause permanent joint distruction
auto immune disease
progressive/chronic disease
affect in symmetrical pattern
affect people of all age
cause permanent distruction of joint
affect both male and female
3. Etiology
RA is caused by combination of genetic and environmental factor that trigger an
abnormal immune response
Possible cause -
Genetic factor- Certain genes that play a role in the immune system are
associated with RA development
Environmental factor- certain infectious agents, such as some viruses
or bacteria may increase suseptibility to RA
Other factor- some hormonal factor may promote RA development in
combination with genetic factors and environmental exposure
4. Sign and symptoms
Symmetrical joint pain
Swelling of joint
Joint stiffness
Low grade fever
Fatigue
Malaise
redness on joint
Warmth joiny
Loss of fuction
5. Treatment
The goal of treatment of RA -
Relieve pain and inflammation
Prevent joint destruction
Preserve and improve a patient functional activity
Maintain patient normal life
Types of treatment-
There are two types of treatment
1)Non pharmacological
2)Pharmacological
7. Pharmacological Treatment
Traditionally treatment for RA was introduce in a stepwise ‘pyramidal’ manner-
First line drug - such as analgesic and NSAIDS are used
Second line drug - such as Sulfasalazine
Third line drug- such as Azathioprine
Note-
First line drugs are used to relieve pain and second or third line drugs are used
when symptoms are adequately not controlled.
8. NSAID act by direct inhibition of COX-1 and COX-2 by blocking COX
enzyme site. Cyclo-oxygenase converts the fatty acid arachidonic into
prostaglandin which cause inflammation.
Ex- Aspirin ( dose – 4 to 6 gm/day)
Ibuprofen ( dose – 400 to 600 mg/day)
Side Effect-
GIT complication like ulcer.
GI toxicity.
Intolerence like Dyspepsia.
NSAID
(Non-steroidal anti-inflammatory drug)
9. Preventive therapies for side effect of NSAID
Misoprostol - which is a synthetic prostaglandin effective in prevention of
NSAID induced ulcer by enhancing mucus secretion
Omeprazole - It is also effective in the prevention of NSAID induced GI
complication .It is more effective than misoprostol in maintaining remission
Ranitidine – H 2 receptor antagonist used in the prevention of NSAID
induced GI toxicity
10. DMARD
(Disease modifying anti-rheumatic drug)
Have a major role in managing rheumatic arthritis
Have very different mechanism of action and chemical structure
Has been shown to slow progression of disease
Choice of these drugs depend upon the balance between adverse effect and
efficacy
Slow onset of action
Response to treatment usually expected within 4- 6 month
Ex- Methotrexate , Sulfasalazine , Cyclosporin , Azathioprine , Leflunomide etc.
11. SULFASALAZINE
Most commonly prescribed DMARD due to its favourable risk- benefit ratio
Has high continuation rate.
Low rate of serious adverse effect.
Has been shown to disease progression slow.
Dose- initially 500mg once daily
increasing in weekly steps of 500 mg to 1gm twice daily.
Side effect- Nausea , rashes, marrow suppression, reversible male infertility.
To reduce side effect of nausea the dose is usually titrated from 500 mg to 1gm
twice daily .
12. METHOTREXATE
Used in first line drug therapy
Most effective DMARD
Has a high 5 year continuation rate.
And a low incidence of adverse effect at low weekly dose.
Rapid onset of action of 4-6 weeks.
Easy to administer as a single weekly dose
High response rate of 40-50 %.
Dose- 5-25 mg once weekly.
Side effect - hepatic fibrosis, liver toxicity, stomatitis.
To reduce nausea and stomatitis,folic acid is added to methotrexate therapy.
13. Steroid
Mainly corticosteroid is used
Suppress cytokines and produce a rapid improvement in sign and symptoms of
disease.
Potent anti inflammatory effect, inc mobility and reduce deformity of joint.
Ex- Prednisolone, methyl prednisolone acetate.
Oral prednisolone is used to provide temporary relief until a DMARDS become
effective.
Dose- 40 mg for large joint at interval of 1-5 weeks.
( dose depend upon joint size)
Side effect- prophylaxis and osteoporosis.
To reduce side effect- calcium supplement is used with this therapy..
14. LEFLUNOMIDE-New
oral DMARD for RA treatment, isoxazole derivative
Has both anti inflammatory and immuno modulatory properties
Act by inhibiting the synthesis of DNA and RNA in immuno response cell
particularly T-cell
Also inhibit the production of cytokines
Rapid on set of action
Side effect- GIT disturbance, alopecia ,hypertension
Dose- 100 mg given once a week ( up to 3 weeks)
To reduce side effect- avoide alcohal, not use in pregnant lady, reduce salt
absorption
15. TNF-alfa inhibitor
It is also a inflammatory mediator that contributes to the pathogenesis of
synovitis and joint destruction substance produced by our body.
These inhibitor can help reduce pain ,stiffness and tender or swollen joint
Ex- Etanercept
is a recombinant human soluble TNF receptor
mechanism of action is competitive inhibition of TNF , binding to cell
surface receptor and prevent TNF mediate cellular response
given subcutaneously
Dose – 4-6 mg/kg( every week)
Side effect- injection site reaction , rhinitis